Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 60 full-time employees. The company went IPO on 2021-06-11. Its initial focus is on developing a class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. The company is developing a pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr. PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. Its TRACIr program targets PD-L1xCD28.